DK166713B1 - Fremgangsmaade til inaktivering af stoffer, der foraarsager uforenelighedsreaktioner i immunglobulinholdige blodfraktioner til terapeutisk eller profylaktisk anvendelse samt fremstilling af en immunglobulinholdig blodfraktion - Google Patents
Fremgangsmaade til inaktivering af stoffer, der foraarsager uforenelighedsreaktioner i immunglobulinholdige blodfraktioner til terapeutisk eller profylaktisk anvendelse samt fremstilling af en immunglobulinholdig blodfraktion Download PDFInfo
- Publication number
- DK166713B1 DK166713B1 DK131284A DK131284A DK166713B1 DK 166713 B1 DK166713 B1 DK 166713B1 DK 131284 A DK131284 A DK 131284A DK 131284 A DK131284 A DK 131284A DK 166713 B1 DK166713 B1 DK 166713B1
- Authority
- DK
- Denmark
- Prior art keywords
- immunoglobulin
- fraction
- treated
- blood
- enzymes
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 32
- 210000004369 blood Anatomy 0.000 title claims abstract description 16
- 239000008280 blood Substances 0.000 title claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 title claims description 5
- 230000000069 prophylactic effect Effects 0.000 title claims 2
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- 230000002779 inactivation Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 9
- 239000012876 carrier material Substances 0.000 claims abstract description 6
- 230000000415 inactivating effect Effects 0.000 claims abstract description 4
- 238000005194 fractionation Methods 0.000 claims abstract description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 42
- 102000018358 immunoglobulin Human genes 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 241000282472 Canis lupus familiaris Species 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 108090000631 Trypsin Proteins 0.000 claims description 14
- 102000004142 Trypsin Human genes 0.000 claims description 14
- 230000036772 blood pressure Effects 0.000 claims description 12
- 239000012588 trypsin Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 230000002227 vasoactive effect Effects 0.000 claims description 11
- 241000700198 Cavia Species 0.000 claims description 10
- 210000000265 leukocyte Anatomy 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 229920002684 Sepharose Polymers 0.000 claims description 6
- 230000002741 bronchospastic effect Effects 0.000 claims description 6
- 108010093096 Immobilized Enzymes Proteins 0.000 claims description 5
- 108090000317 Chymotrypsin Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229960002376 chymotrypsin Drugs 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004044 bronchoconstricting agent Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 239000010836 blood and blood product Substances 0.000 abstract description 3
- 229940125691 blood product Drugs 0.000 abstract description 3
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 32
- 230000037396 body weight Effects 0.000 description 20
- 229940027941 immunoglobulin g Drugs 0.000 description 16
- 238000010828 elution Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 230000003171 anti-complementary effect Effects 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 108010074605 gamma-Globulins Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 5
- 230000000610 leukopenic effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000001361 intraarterial administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- RXHSGRQJJBSBPN-UHFFFAOYSA-L [Na+].[Na+].Cl.OP([O-])([O-])=O Chemical compound [Na+].[Na+].Cl.OP([O-])([O-])=O RXHSGRQJJBSBPN-UHFFFAOYSA-L 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012475 sodium chloride buffer Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 208000007746 Immunologic Deficiency Syndromes Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- IZQZNLBFNMTRMF-UHFFFAOYSA-N acetic acid;phosphoric acid Chemical compound CC(O)=O.OP(O)(O)=O IZQZNLBFNMTRMF-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 108010079570 uropepsin Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Catalysts (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK152486A DK152486A (da) | 1983-03-16 | 1986-04-03 | Fremgangsmaade til bestemmelse af stoffer, der foraarsager uforenelighedsreaktioner i blodprodukter, der skal anvendes terapeutisk og profylaktisk, samt anvendelse af fremgangsmaaden |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT93183 | 1983-03-16 | ||
| AT0093183A AT383739B (de) | 1983-03-16 | 1983-03-16 | Verfahren zur inaktivierung von unvertraeglichkeitsreaktionen verursachenden substanzen in immunglobulinhaeltigen blutfraktionen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK131284D0 DK131284D0 (da) | 1984-02-29 |
| DK131284A DK131284A (da) | 1984-09-17 |
| DK166713B1 true DK166713B1 (da) | 1993-07-05 |
Family
ID=3503142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK131284A DK166713B1 (da) | 1983-03-16 | 1984-02-29 | Fremgangsmaade til inaktivering af stoffer, der foraarsager uforenelighedsreaktioner i immunglobulinholdige blodfraktioner til terapeutisk eller profylaktisk anvendelse samt fremstilling af en immunglobulinholdig blodfraktion |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4886758A (ja) |
| EP (1) | EP0120835B1 (ja) |
| JP (2) | JPS601136A (ja) |
| AT (2) | AT383739B (ja) |
| CA (2) | CA1216792A (ja) |
| DE (1) | DE3482845D1 (ja) |
| DK (1) | DK166713B1 (ja) |
| ES (1) | ES8604990A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK166763B1 (da) * | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| FR2582515B1 (fr) * | 1985-05-30 | 1988-11-04 | Merieux Inst | Procede de preparation de gamma-gobulines administrables par voie intraveineuse et gamma-globulines obtenues |
| DE3609954A1 (de) * | 1986-03-25 | 1987-10-01 | Biotest Pharma Gmbh | Verfahren zur herstellung eines den blutgerinnungsfaktor viii in ankonzentrierter form enthaltenden praeparates |
| AT390560B (de) * | 1986-05-30 | 1990-05-25 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
| AT388501B (de) * | 1987-02-12 | 1989-07-25 | Immuno Ag | Verfahren zur herstellung von parenteral verabreichbaren blutprodukten |
| AT391810B (de) * | 1988-02-26 | 1990-12-10 | Immuno Ag | Verwendung von chymotrypsin zum unwirksammachen des praekallikrein-aktivators |
| US5328834A (en) * | 1989-09-08 | 1994-07-12 | Unisyn Technologies, Inc. | Method for preparing immunoglobulin fragments |
| AT396937B (de) * | 1992-04-06 | 1993-12-27 | Immuno Ag | Verfahren zur aktivierung von blutgerinnungsfaktoren |
| EP0835880A1 (de) * | 1996-10-14 | 1998-04-15 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation |
| JP4830768B2 (ja) * | 2006-05-10 | 2011-12-07 | 日亜化学工業株式会社 | 半導体発光装置及び半導体発光装置の製造方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1148037B (de) * | 1961-10-11 | 1963-05-02 | Behringwerke Ag | Verfahren zur Herstellung eines desaggregierten, das Komplementsystem nicht beeinflussenden Gammaglobulins |
| CH392780A (de) * | 1961-12-07 | 1965-05-31 | Schweiz Rotes Kreuz | Verfahren zur Herstellung von intravenös anwendbaren Antikörperpräparaten humanen Ursprungs |
| AU469815B2 (en) * | 1971-04-14 | 1973-10-18 | Anti-inflammatory compositions | |
| JPS5548392A (en) * | 1978-02-17 | 1980-04-07 | Toyo Jozo Co Ltd | Novel immobilizing material combined with biologically active substance, its preparation, device comprising it, method, and preparation of support |
| AT359641B (de) * | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
| DE2846412A1 (de) * | 1978-10-25 | 1980-05-08 | Behringwerke Ag | Mittel zur behandlung allergischer reaktionen |
| JPS567721A (en) * | 1979-07-02 | 1981-01-27 | Mochida Pharmaceut Co Ltd | Preparation of immunoglobulin for intravenous injection |
| JPS5615215A (en) * | 1979-07-14 | 1981-02-14 | Nippon Sekijiyuujishiya | Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel |
| JPS57206608A (en) * | 1981-05-29 | 1982-12-18 | Mochida Pharmaceut Co Ltd | Production of gamma-globulin for intravenous injection |
-
1983
- 1983-03-16 AT AT0093183A patent/AT383739B/de not_active IP Right Cessation
-
1984
- 1984-02-29 DK DK131284A patent/DK166713B1/da not_active IP Right Cessation
- 1984-03-08 CA CA000449165A patent/CA1216792A/en not_active Expired
- 1984-03-12 EP EP84890044A patent/EP0120835B1/de not_active Expired - Lifetime
- 1984-03-12 DE DE8484890044T patent/DE3482845D1/de not_active Expired - Lifetime
- 1984-03-12 AT AT84890044T patent/ATE55059T1/de not_active IP Right Cessation
- 1984-03-14 ES ES530592A patent/ES8604990A1/es not_active Expired
- 1984-03-15 JP JP59050804A patent/JPS601136A/ja active Granted
-
1986
- 1986-07-08 JP JP61161768A patent/JPH0684965B2/ja not_active Expired - Lifetime
- 1986-09-04 CA CA000517515A patent/CA1248447A/en not_active Expired
- 1986-09-15 US US06/907,652 patent/US4886758A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6296857A (ja) | 1987-05-06 |
| EP0120835A2 (de) | 1984-10-03 |
| ATA93183A (de) | 1987-01-15 |
| JPH0585529B2 (ja) | 1993-12-07 |
| AT383739B (de) | 1987-08-10 |
| DK131284D0 (da) | 1984-02-29 |
| CA1248447A (en) | 1989-01-10 |
| DE3482845D1 (de) | 1990-09-06 |
| CA1216792A (en) | 1987-01-20 |
| EP0120835A3 (en) | 1986-12-30 |
| EP0120835B1 (de) | 1990-08-01 |
| US4886758A (en) | 1989-12-12 |
| ES8604990A1 (es) | 1986-04-01 |
| ATE55059T1 (de) | 1990-08-15 |
| DK131284A (da) | 1984-09-17 |
| ES530592A0 (es) | 1986-04-01 |
| JPH0684965B2 (ja) | 1994-10-26 |
| JPS601136A (ja) | 1985-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK166763B1 (da) | Immunoglobulin-g-holdig fraktion | |
| US4216205A (en) | Process of preparing a serum protein composition for intravenous application | |
| CA1329542C (en) | Plasma and recombinant protein formulations in low ionic strength media | |
| CA1341505C (en) | Intravenously administered polyclonal immunoglobulin preparation containing igm and method of manufacture | |
| RU2266914C2 (ru) | Способ получения igg | |
| US4876088A (en) | Gamma-globulin injectable solutions containing sorbitol | |
| EP0479597B1 (en) | Process for producing secretory immunoglobulin-A preparations | |
| DK166713B1 (da) | Fremgangsmaade til inaktivering af stoffer, der foraarsager uforenelighedsreaktioner i immunglobulinholdige blodfraktioner til terapeutisk eller profylaktisk anvendelse samt fremstilling af en immunglobulinholdig blodfraktion | |
| Barandun et al. | Clinical tolerance and catabolism of plasmin-treatedγ-globulin for intravenous application | |
| EP0253313B1 (en) | Process for heat treating chemically unmodified gamma-globulin | |
| JPH0365327B2 (ja) | ||
| AU725134B2 (en) | Method of producing an IgM preparation for intravenous application | |
| US6646108B1 (en) | Process for isolating IgG and IgA | |
| JPH04346934A (ja) | γ−グロブリンの液状製剤 | |
| US5234685A (en) | Method of determining incompatibility-reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances | |
| JPS5872526A (ja) | モノクロ−ルｈｂｓ抗体の製造方法 | |
| SI7912259A8 (sl) | Postopek za pripravo protitelesa vsebujočega imunglobulinskega pripravka za intravenozno dajanje | |
| JPH07103045B2 (ja) | 非化学修飾γ−グロブリンの加熱処理方法 | |
| US20080044430A1 (en) | Agent for Stimulating the Production of a Blood Coagulation Factor VIII | |
| Solutions et al. | Aluminium in Human | |
| JPS6345229A (ja) | 静注用免疫グロブリン製剤 | |
| JPH0381229A (ja) | 抗ａｔｌウイルス抗体陽性静注用免疫グロブリン製剤の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHB | Application shelved due to non-payment | ||
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |